FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
|Articles|August 28, 2018
Supplements and Featured Publications
- Whitepaper: Optimal Oncology Alternative Payment Models
Whitepaper: Optimal Oncology Alternative Payment Models
Advertisement
The way forward for alternative payment models in oncology
This whitepaper publication from Tapestry Networks reflects views of leading thinkers in value-based payment reform and oncology, as well as results from a recent workshop. It offers both a synthesis of stakeholder perspectives and recommendations for improving oncology APMs.
Advertisement
Related to this article
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Boarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Advertisement
Advertisement
Trending on AJMC
1
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
2
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
5